Gladman D D, Antoni C, Mease P, Clegg D O, Nash P
University of Toronto, Toronto Western Research Institute, Psoriatic Arthritis Program, Toronto Western Hospital, Toronto, Ontario M5T 2S8, Canada.
Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii14-7. doi: 10.1136/ard.2004.032482.
Psoriatic arthritis (PsA) has been defined as a unique inflammatory arthritis associated with psoriasis. Its exact prevalence is unknown, but estimates vary from 0.3% to 1% of the population. The clinical features described initially are recognised by most experienced clinicians, although they are most distinct in early disease. Initially, PsA typically presents as an oligoarticular and mild disease. However, with time PsA becomes polyarticular, and it is a severe disease in at least 20% of patients. Patients with PsA who present with polyarticular disease are at risk for disease progression. In addition to progression of clinical and radiological damage, health related quality of life is reduced among patients with PsA. It important to note that patients included in recent drug trials resemble patients followed prospectively in a clinic.
银屑病关节炎(PsA)被定义为一种与银屑病相关的独特炎性关节炎。其确切患病率尚不清楚,但估计在人群中的比例为0.3%至1%。最初描述的临床特征为大多数经验丰富的临床医生所认可,尽管在疾病早期最为明显。起初,PsA通常表现为少关节型且病情较轻。然而,随着时间推移,PsA会发展为多关节型,并且至少20%的患者会发展为重症疾病。表现为多关节型疾病的PsA患者有疾病进展的风险。除了临床和放射学损伤的进展外,PsA患者的健康相关生活质量也会下降。需要注意的是,近期药物试验纳入的患者与在诊所进行前瞻性随访的患者相似。